Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 3.37% vs 175.71% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is -52.36% vs -4.01% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 143.64% vs 23.01% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is -70.63% vs -195.98% in Mar 2025
Compare Profit and Loss Results of Oxygenta Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
112.00
115.00
-3.00
-2.61%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
112.00
115.00
-3.00
-2.61%
Expenditure (Ex Depriciation)
Stock Adjustments
-8.00
3.00
-11.00
-366.67%
Raw Materials Consumed
110.00
49.00
61.00
124.49%
Power & Fuel Cost
6.00
3.00
3.00
100.00%
Employee Cost
7.00
14.00
-7.00
-50.00%
Operating Expenses
8.00
4.00
4.00
100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
2.00
-2.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
5.00
-5.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
128.00
88.00
40.00
45.45%
Operating Profit (PBDIT) excl Other Income
-15.00
26.00
-41.00
-157.69%
Other Income
0.00
9.00
-9.00
-100.00%
Operating Profit (PBDIT)
-15.00
35.00
-50.00
-142.86%
Interest
4.00
0.00
4.00
0%
Profit before Depriciation and Tax
-19.00
35.00
-54.00
-154.29%
Depreciation
2.00
2.00
0.00
0.00%
Profit Before Taxation & Exceptional Items
-22.00
33.00
-55.00
-166.67%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-22.00
32.00
-54.00
-168.75%
Provision for Tax
-4.00
8.00
-12.00
-150.00%
Profit After Tax
-17.00
24.00
-41.00
-170.83%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
-74.00
147.00
-221.00
-150.34%
Profit Available for appropriations
-91.00
171.00
-262.00
-153.22%
Appropriations
-91.00
171.00
-262.00
-153.22%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-4.75
67.61
-72.36
-107.03%
Profit And Loss - Net Sales
Net Sales 112.98 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.37% vs 175.71% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) -15.37 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -52.36% vs -4.01% in Mar 2025
Profit And Loss - Interest
Interest 4.78 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 143.64% vs 23.01% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax -17.57 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -70.63% vs -195.98% in Mar 2025
